
## Eric D Peterson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4988427/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375, 2423-2434.	27.0	1,265
2	Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2010, 303, 1716.	7.4	852
3	Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2006, 295, 1912.	7.4	588
4	Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack. Circulation, 2009, 119, 107-115.	1.6	505
5	2016 Annual Report of TheÂSocietyÂofÂThoracic Surgeons/AmericanÂCollege of Cardiology Transcatheter Valve TherapyÂRegistry. Journal of the American College of Cardiology, 2017, 69, 1215-1230.	2.8	429
6	Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2015, 313, 1019.	7.4	412
7	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. Journal of the American College of Cardiology, 2016, 68, 2597-2604.	2.8	401
8	Racial-Ethnic Disparities in Stroke Care: The American Experience. Stroke, 2011, 42, 2091-2116.	2.0	397
9	Prediction of operative mortality after valve replacement surgery. Journal of the American College of Cardiology, 2001, 37, 885-892.	2.8	380
10	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. JAMA Cardiology, 2018, 3, 44.	6.1	346
11	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation, 2015, 131, 451-458.	1.6	283
12	Annual Outcomes With TranscatheterÂValve Therapy. Journal of the American College of Cardiology, 2015, 66, 2813-2823.	2.8	232
13	Relationship Between Diabetes Mellitus and Long-term Survival After Coronary Bypass and Angioplasty. Circulation, 1997, 96, 2551-2556.	1.6	225
14	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. Circulation, 2015, 131, 488-494.	1.6	224
15	Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. American Heart Journal, 2008, 156, 1045-1055.	2.7	216
16	Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. American Heart Journal, 2015, 170, 141-148.e1.	2.7	211
17	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	6.1	196
18	A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network). Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 491-499.	2.2	187

#	Article	IF	CITATIONS
19	Comparing risk-adjustment methods for provider profiling. , 1998, 16, 2645-2664.		186
20	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. JAMA Cardiology, 2016, 1, 282.	6.1	182
21	Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery. Circulation, 2014, 130, 1445-1451.	1.6	181
22	Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. JAMA - Journal of the American Medical Association, 2018, 319, 463.	7.4	180
23	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2017, 317, 1057.	7.4	179
24	Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 393-402.	2.2	173
25	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	2.7	161
26	Temporal Trends and Geographic Variation of Lower-Extremity Amputation in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2012, 60, 2230-2236.	2.8	158
27	The Learning Curve for Transradial Percutaneous Coronary Intervention Among Operators in the United States. Circulation, 2014, 129, 2277-2286.	1.6	156
28	Sex Differences in the Use of Statins in Community Practice. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005562.	2.2	155
29	Successful Linking of The Society of Thoracic Surgeons Adult Cardiac Surgery Database to Centers for Medicare and Medicaid Services Medicare Data. Annals of Thoracic Surgery, 2010, 90, 1150-1157.	1.3	148
30	Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): Results from a National Data Validation Audit. American Heart Journal, 2012, 163, 392-398.e1.	2.7	145
31	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care, 2016, 39, 2304-2310.	8.6	142
32	Public Reporting of Cardiac Surgery Performance: Part 1—History, Rationale, Consequences. Annals of Thoracic Surgery, 2011, 92, S2-S11.	1.3	141
33	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart Journal. 2015. 169. 472-478.e5.	2.7	140
34	Trends in Settings for Peripheral Vascular Intervention and the Effect of Changes inÂthe Outpatient Prospective PaymentÂSystem. Journal of the American College of Cardiology, 2015, 65, 920-927.	2.8	138
35	Rates of Cardiopulmonary Resuscitation Training in the United States. JAMA Internal Medicine, 2014, 174, 194.	5.1	131
36	Effects of Virtual Exercise Rehabilitation In-Home Therapy Compared with Traditional Care After Total Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2020, 102, 101-109.	3.0	131

#	Article	IF	CITATIONS
37	Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. Circulation, 2017, 135, 128-139.	1.6	129
38	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	127
39	Early Anticoagulation of Bioprosthetic Aortic Valves in Older Patients. Journal of the American College of Cardiology, 2012, 60, 971-977.	2.8	122
40	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 167, 735-742.e2.	2.7	120
41	Socioeconomic disparities in outcomes after acute myocardial infarction. American Heart Journal, 2007, 153, 313-319.	2.7	119
42	Gait Speed Predicts 30-Day Mortality After Transcatheter Aortic Valve Replacement. Circulation, 2016, 133, 1351-1359.	1.6	119
43	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Circulation, 2019, 139, 1603-1611.	1.6	115
44	Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European Journal of Preventive Cardiology, 2015, 22, 1321-1327.	1.8	112
45	Ingredients of Successful Interventions to Improve Medication Adherence. JAMA - Journal of the American Medical Association, 2013, 310, 2611.	7.4	111
46	Outcomes of PCI in Relation to ProceduralÂCharacteristics and OperatorÂVolumes inÂthe United States. Journal of the American College of Cardiology, 2017, 69, 2913-2924.	2.8	104
47	Validated, Electronic Health Record Deployable Prediction Models for Assessing Patient Risk of 30-Day Rehospitalization and Mortality in Older Heart Failure Patients. JACC: Heart Failure, 2013, 1, 245-251.	4.1	95
48	Proportion of US Adults Potentially Affected by the 2014 Hypertension Guideline. JAMA - Journal of the American Medical Association, 2014, 311, 1424.	7.4	95
49	The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. American Heart Journal, 2016, 175, 193-201.e3.	2.7	95
50	Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. European Journal of Preventive Cardiology, 2015, 22, 317-325.	1.8	94
51	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use. JAMA Cardiology, 2018, 3, 739.	6.1	94
52	Public Reporting of Cardiac Surgery Performance: Part 2—Implementation. Annals of Thoracic Surgery, 2011, 92, S12-S23.	1.3	93
53	Predictors and Prognostic Implications ofÂIncident Heart Failure in Patients WithÂPrevalent Atrial Fibrillation. JACC: Heart Failure, 2017, 5, 44-52.	4.1	91
54	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. Circulation, 2016, 134, 517-526.	1.6	90

#	Article	IF	CITATIONS
55	Participation in Cardiac Rehabilitation Programs Among Older Patients After Acute Myocardial Infarction. JAMA Internal Medicine, 2015, 175, 1700.	5.1	89
56	Outcomes of Patients With AcuteÂMyocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant andÂDualÂAntiplatelet Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1880-1889.	2.9	87
57	Impact of an interactive video on decision making of patients with ischemic heart disease. Journal of General Internal Medicine, 1996, 11, 373-376.	2.6	86
58	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation, 2017, 135, 323-333.	1.6	86
59	Incidence, Management, and Associated Clinical Outcomes of New-Onset AtrialÂFibrillation Following TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1746-1756.	2.9	84
60	Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. American Heart Journal, 2016, 174, 29-36.	2.7	82
61	Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	82
62	Transcatheter Versus Surgical AorticÂValveÂReplacement. Journal of the American College of Cardiology, 2017, 70, 439-450.	2.8	82
63	Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology, 2016, 1, 147.	6.1	80
64	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace, 2018, 20, 1-11.	1.7	80
65	Excess Costs Associated With Complications and Prolonged Length of Stay After Congenital Heart Surgery. Annals of Thoracic Surgery, 2014, 98, 1660-1666.	1.3	79
66	Good Clinical Practice Guidance and Pragmatic Clinical Trials. Circulation, 2016, 133, 872-880.	1.6	79
67	Association of Neighborhood Demographics With Out-of-Hospital Cardiac Arrest Treatment and Outcomes. JAMA Cardiology, 2017, 2, 1110.	6.1	78
68	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. JAMA Cardiology, 2018, 3, 54.	6.1	77
69	Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States. JAMA Cardiology, 2019, 4, 444.	6.1	75
70	The Association of Transcatheter Aortic Valve Replacement Availability and Hospital Aortic ValveÂReplacement Volume and Mortality in theÂUnited States. Annals of Thoracic Surgery, 2014, 98, 2016-2022.	1.3	74
71	Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery. JAMA Surgery, 2014, 149, 798.	4.3	74
72	Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry. American Heart Journal, 2014, 168, 213-219.e1.	2.7	73

#	Article	IF	CITATIONS
73	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. Circulation, 2014, 129, 2005-2012.	1.6	73
74	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2018, 320, 2231.	7.4	72
75	Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes. Circulation, 2016, 133, 131-138.	1.6	70
76	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. JAMA Neurology, 2019, 76, 1192.	9.0	70
77	Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. American Heart Journal, 2019, 212, 113-119.	2.7	70
78	Management and outcomes of patients with atrial fibrillation and <i>a history of</i> cancer: the ORBIT-AF registry. European Heart Journal Quality of Care & Clinical Outcomes, 2017, 3, 192-197.	4.0	69
79	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 499-508.	1.0	68
80	Normal Coronary Rates for Elective Angiography in the Veterans Affairs Healthcare System. Journal of the American College of Cardiology, 2014, 63, 417-426.	2.8	67
81	Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction. American Heart Journal, 2015, 170, 855-864.	2.7	67
82	Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. Stroke, 2016, 47, 836-842.	2.0	67
83	Gerotechnology for Older Adults With Cardiovascular Diseases. Journal of the American College of Cardiology, 2020, 76, 2650-2670.	2.8	66
84	Development of a Clinical Registry-Based 30-Day Readmission Measure for Coronary Artery Bypass Grafting Surgery. Circulation, 2014, 130, 399-409.	1.6	65
85	Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. American Heart Journal, 2014, 168, 160-167.	2.7	62
86	Patient factors associated with quality of life in atrial fibrillation. American Heart Journal, 2016, 182, 135-143.	2.7	62
87	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care, 2017, 40, 1763-1770.	8.6	60
88	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care, 2018, 41, 596-603.	8.6	59
89	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. Journal of the American College of Cardiology, 2015, 65, 1633-1639.	2.8	58
90	Longâ€Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. Journal of the American Heart Association, 2018, 7, .	3.7	58

#	Article	IF	CITATIONS
91	ACCF/AHA 2010 Position Statement on Composite Measures for Healthcare Performance Assessment. Journal of the American College of Cardiology, 2010, 55, 1755-1766.	2.8	57
92	Central venous pressure after coronary artery bypass surgery: Does it predict postoperative mortality or renal failure?. Journal of Critical Care, 2014, 29, 1006-1010.	2.2	57
93	Use of Open Access Platforms for Clinical Trial Data. JAMA - Journal of the American Medical Association, 2016, 315, 1283.	7.4	57
94	Sex and Race/Ethnicity–Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S36-44.	2.2	57
95	Machine Learning, Predictive Analytics, and Clinical Practice. JAMA - Journal of the American Medical Association, 2019, 322, 2283.	7.4	57
96	Trends in the Use and Outcomes of Ventricular AssistÂDevices Among MedicareÂBeneficiaries, 2006ÂThrough 2011. Journal of the American College of Cardiology, 2014, 63, 1395-1404.	2.8	56
97	Association Between Hospital Process Composite Performance and Patient Outcomes After In-Hospital Cardiac Arrest Care. JAMA Cardiology, 2016, 1, 37.	6.1	56
98	Eliminating Racial and Ethnic Disparities in Cardiac Care. New England Journal of Medicine, 2009, 360, 1172-1174.	27.0	55
99	Early Medication Nonadherence After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 347-356.	2.2	55
100	Utility of Socioeconomic Status in Predicting 30-Day Outcomes After Heart Failure Hospitalization. Circulation: Heart Failure, 2015, 8, 473-480.	3.9	55
101	An Initial Evaluation of the Impact of Pokémon GO on Physical Activity. Journal of the American Heart Association, 2017, 6, .	3.7	54
102	Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2015, 314, 1973.	7.4	53
103	Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2017, 189, 40-47.	2.7	53
104	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 383-392.	2.2	52
105	Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke. Stroke, 2016, 47, 1294-1302.	2.0	52
106	Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. Stroke, 2017, 48, 1810-1817.	2.0	52
107	Sitagliptin and risk of fractures in type 2 diabetes: <scp>R</scp> esults from the <scp>TECOS</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 78-86.	4.4	52
108	Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. American Heart Journal, 2015, 169, 39-44.e2.	2.7	51

#	Article	IF	CITATIONS
109	Moving From Clinical Trials to Precision Medicine. JAMA - Journal of the American Medical Association, 2016, 315, 1713.	7.4	51
110	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 2433.	7.4	50
111	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care, 2017, 40, 494-501.	8.6	50
112	Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction. JAMA Cardiology, 2017, 2, 750.	6.1	50
113	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 585-593.	3.9	49
114	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. American Journal of Medicine, 2016, 129, 592-599.e1.	1.5	49
115	Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care, 2017, 40, 164-170.	8.6	49
116	Inclusion of Functional Status MeasuresÂinÂthe Risk Adjustment of 30-Day Mortality After Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2018, 11, 581-589.	2.9	49
117	Statin Use and Adverse Effects Among Adults >75ÂYears of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. Journal of the American Heart Association, 2018, 7, .	3.7	49
118	Impact of Bleeding on Quality of Life in Patients on DAPT. Journal of the American College of Cardiology, 2016, 67, 59-65.	2.8	48
119	Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation, 2017, 135, 1024-1035.	1.6	48
120	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. JAMA Cardiology, 2018, 3, 1192.	6.1	48
121	Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. Thrombosis Research, 2019, 182, 159-166.	1.7	48
122	Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e001403.	3.9	47
123	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1193-1203.	1.6	47
124	Association Between Divorce and Risks for Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 244-251.	2.2	46
125	Impact of Insurance Status on Outcomes and Use of Rehabilitation Services in Acute Ischemic Stroke: Findings From Get With The Guidelinesâ€ <del>S</del> troke. Journal of the American Heart Association, 2016, 5, .	3.7	46
126	Has Public Reporting of Hospital Readmission Rates AffectedÂPatient Outcomes?. Journal of the American College of Cardiology, 2016, 67, 963-972.	2.8	46

#	Article	IF	CITATIONS
127	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 793-799.	4.8	45
128	Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction. Circulation, 2015, 132, 174-181.	1.6	45
129	Association of Body Mass Index WithÂCareÂand Outcomes in Patients WithÂAtrialÂFibrillation. JACC: Clinical Electrophysiology, 2016, 2, 355-363.	3.2	45
130	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. American Heart Journal, 2020, 219, 47-57.	2.7	45
131	Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. American Heart Journal, 2020, 224, 47-53.	2.7	44
132	Open Access to Clinical Trials Data. JAMA - Journal of the American Medical Association, 2014, 312, 1002.	7.4	43
133	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. Circulation, 2015, 132, 1404-1413.	1.6	43
134	Variation in Hospital Risk–Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 560-565.	2.2	43
135	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBITâ€AF (Outcomes Registry for Better Informed Treatment for Atrial) Tj ETQq1	1 <b>9.7</b> 8431	14 <b>4g</b> BT /Over
136	Sustained sexâ€based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. Clinical Cardiology, 2018, 41, 758-768.	1.8	43
137	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. JAMA Cardiology, 2019, 4, 375.	6.1	43
138	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. Circulation, 2019, 139, 458-472.	1.6	43
139	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBITâ€AF). Journal of the American Heart Association, 2015, 4, e002031.	3.7	41
140	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003070.	3.9	41
141	Trends in Robotic-Assisted Coronary Artery Bypass Grafts: A Study of The Society of Thoracic Surgeons Adult Cardiac Surgery Database, 2006 to 2012. Annals of Thoracic Surgery, 2016, 102, 140-146.	1.3	41
142	Association of Hospital and Physician Characteristics and Care Processes With Racial Disparities in Procedural Outcomes Among Contemporary Patients Undergoing Coronary Artery Bypass Grafting Surgery. Circulation, 2016, 133, 124-130.	1.6	41
143	The New 2017 ACC/AHA Guidelines "Up the Pressure―on Diagnosis and Treatment of Hypertension. JAMA - Journal of the American Medical Association, 2017, 318, 2083.	7.4	41
144	Trends of blood pressure control in the U.S. during the COVID-19 pandemic. American Heart Journal, 2022, 247, 15-23.	2.7	40

#	Article	IF	CITATIONS
145	Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. Journal of the American College of Cardiology, 2016, 67, 1981-1990.	2.8	39
146	Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. Journal of the American College of Cardiology, 2020, 76, 653-664.	2.8	39
147	2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Annals of Thoracic Surgery, 2017, 103, 1021-1035.	1.3	38
148	The Project Baseline Health Study: a step towards a broader mission to map human health. Npj Digital Medicine, 2020, 3, 84.	10.9	38
149	Developing a Risk Model for In-Hospital Adverse Events Following Implantable Cardioverter-Defibrillator Implantation. Journal of the American College of Cardiology, 2014, 63, 788-796.	2.8	37
150	Race and Sex Differences in Post–Myocardial Infarction Angina Frequency and Risk of 1-Year Unplanned Rehospitalization. Circulation, 2017, 135, 532-543.	1.6	37
151	Unexplained Variation for Hospitals' Use of Inpatient Rehabilitation and Skilled Nursing Facilities After an Acute Ischemic Stroke. Stroke, 2017, 48, 2836-2842.	2.0	37
152	Quality-Cost Relationship in Congenital Heart Surgery. Annals of Thoracic Surgery, 2015, 100, 1416-1421.	1.3	36
153	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. JAMA - Journal of the American Medical Association, 2014, 311, 2209.	7.4	35
154	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. Stroke, 2014, 45, 3243-3250.	2.0	35
155	Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 929-935.	2.2	35
156	Cumulative Incidence of Death and Rehospitalization Among the Elderly in the FirstÂYear after NSTEMI. American Journal of Medicine, 2015, 128, 582-590.	1.5	35
157	Guidelines for Cardiovascular Risk Reduction in Patients With Type 2ÂDiabetes. Journal of the American College of Cardiology, 2022, 79, 1849-1857.	2.8	34
158	Impact of Patient Characteristics on Hospital-Level Outcomes Assessment in Congenital Heart Surgery. Annals of Thoracic Surgery, 2015, 100, 1071-1077.	1.3	33
159	Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. JAMA - Journal of the American Medical Association, 2016, 316, 661.	7.4	33
160	Hospital Variation in Home-Time After Acute Ischemic Stroke. Stroke, 2016, 47, 2627-2633.	2.0	33
161	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non–Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the) Tj ETQq1 1 C Iournal of Cardiology, 2017, 119, 1590-1595.	.784314 rş 1.6	gBT <sub>3</sub> /Overloc
162	Racial Differences in the Use of Aortic Valve Replacement for Treatment of Symptomatic Severe Aortic Valve Stenosis in the Transcatheter Aortic Valve Replacement Era. Journal of the American Heart Association, 2020, 9, e015879.	3.7	32

#	Article	IF	CITATIONS
163	Recommendations for Treating Hypertension. JAMA - Journal of the American Medical Association, 2014, 311, 474.	7.4	31
164	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. American Journal of Medicine, 2015, 128, 426.e1-426.e9.	1.5	31
165	Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non–ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2017, 2, 36.	6.1	31
166	Effect of a Quality of Care Improvement Initiative in Patients With Acute Coronary Syndrome in Resource-Constrained Hospitals in China. JAMA Cardiology, 2019, 4, 418.	6.1	31
167	The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults. Journal of General Internal Medicine, 2020, 35, 1701-1708.	2.6	31
168	Guideline Implementation Research: Exploring the Gap between Evidence and Practice in the CRUSADE Quality Improvement Initiative. Academic Emergency Medicine, 2007, 14, 949-954.	1.8	30
169	Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure. JACC: Heart Failure, 2013, 1, 445-453.	4.1	30
170	Check It, Change It. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 828-834.	2.2	30
171	Differences in Short-Term Versus Long-Term Outcomes of Older Black Versus White Patients With Myocardial Infarction. Circulation, 2014, 130, 659-667.	1.6	30
172	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC: Heart Failure, 2015, 3, 159-167.	4.1	30
173	Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence. JAMA - Journal of the American Medical Association, 2016, 316, 2041.	7.4	30
174	Representativeness of a HeartÂFailure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	4.1	30
175	Successful linking of the Society of Thoracic Surgeons Database to Social Security data to examine the accuracy of Society of Thoracic Surgeons mortality data. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 976-983.	0.8	29
176	Variation and Trends in the Documentation of National Institutes of Health Stroke Scale in GWTG-Stroke Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S90-8.	2.2	29
177	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. JAMA Cardiology, 2016, 1, 864.	6.1	29
178	Clinical Effectiveness of Hydralazine–Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2016, 9, e002444.	3.9	29
179	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. American Heart Journal, 2017, 189, 48-58.	2.7	29
180	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	29

#	Article	IF	CITATIONS
181	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism, 2018, 20, 2379-2388.	4.4	29
182	Effectiveness of Telemedicine Visits in Reducing 30â€Day Readmissions Among Patients With Heart Failure During the COVIDâ€19 Pandemic. Journal of the American Heart Association, 2022, 11, e023935.	3.7	29
183	Implementing Critical Pathways and a Multidisciplinary Team Approach to Cardiovascular Disease Management. American Journal of Cardiology, 2008, 102, 47G-56G.	1.6	28
184	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	3.9	28
185	Hospital Variation in Functional Recovery After Stroke. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	28
186	Association of Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA - Journal of the American Medical Association, 2022, 327, 760.	7.4	28
187	The Impact of Extreme-Risk Cases on Hospitals' Risk-Adjusted Percutaneous Coronary Intervention Mortality Ratings. JACC: Cardiovascular Interventions, 2015, 8, 10-16.	2.9	27
188	Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. Stroke, 2016, 47, 2347-2354.	2.0	27
189	Adverse Change in Employment Status After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004528.	2.2	27
190	Operator-Specific Outcomes. Circulation, 1996, 93, 403-406.	1.6	27
191	Trends in characteristics of cardiovascular clinical trials 2001-2012. American Heart Journal, 2015, 170, 263-272.e2.	2.7	26
192	Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction. Circulation, 2016, 133, 493-501.	1.6	26
193	The Effect of Clinical Care Location onÂClinical Outcomes After PeripheralÂVascular Intervention in Medicare Beneficiaries. JACC: Cardiovascular Interventions, 2017, 10, 1161-1171.	2.9	26
194	Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non–ST‧egment–Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	26
195	The Association Between Lowâ€Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts. Journal of the American Geriatrics Society, 2019, 67, 2560-2567.	2.6	26
196	Outcomes 1 Year After Implantable Cardioverter–Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	25
197	Effect of Procedure and Coronary LesionÂCharacteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 626-634.	2.9	25
198	Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China. American Heart Journal, 2015, 169, 349-355.	2.7	24

#	Article	IF	CITATIONS
199	Treatment, Outcomes, and Adherence to Medication Regimens Among Dual Medicare-Medicaid–Eligible Adults With Myocardial Infarction. JAMA Cardiology, 2016, 1, 787.	6.1	24
200	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	24
201	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes, Obesity and Metabolism, 2017, 19, 1587-1593.	4.4	24
202	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004249.	2.2	24
203	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. Atherosclerosis, 2018, 272, 80-86.	0.8	24
204	Antiarrhythmic Drug Use in Patients <65ÂYears With Atrial Fibrillation and Without Structural Heart Disease. American Journal of Cardiology, 2015, 115, 316-322.	1.6	23
205	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. American Heart Journal, 2015, 169, 175-184.	2.7	23
206	Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATEâ€ACS Study. Journal of the American Heart Association, 2017, 6, .	3.7	23
207	Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1427-1434.	4.4	23
208	The association of Duration of participation in get with the guidelines-resuscitation with quality of Care for in-Hospital Cardiac Arrest. American Heart Journal, 2018, 204, 156-162.	2.7	23
209	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart, 2018, 104, 1850-1858.	2.9	23
210	Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic Attack. JAMA Neurology, 2019, 76, 932.	9.0	23
211	Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy. JAMA Internal Medicine, 2020, 180, 1531.	5.1	23
212	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. European Journal of Heart Failure, 2022, 24, 169-180.	7.1	23
213	Using observational data to estimate prognosis: an example using a coronary artery disease registry. Statistics in Medicine, 2001, 20, 2505-2532.	1.6	22
214	The Impact of Differential Case Ascertainment in Clinical Registry Versus Administrative Data on Assessment of Resource Utilization in Pediatric Heart Surgery. World Journal for Pediatric & Congenital Heart Surgery, 2014, 5, 398-405.	0.8	22
215	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 421-427.	2.2	22
216	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	22

#	Article	IF	CITATIONS
217	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart, 2019, 105, heartjnl-2018-313642.	2.9	22
218	Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. American Heart Journal, 2015, 170, 1227-1233.	2.7	21
219	Access to routine care and risks for 30-day readmission in patients with cardiovascular disease. American Heart Journal, 2018, 196, 9-17.	2.7	21
220	The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice. Journal of Clinical Lipidology, 2019, 13, 725-734.	1.5	21
221	Cardiovascular Biomarkers and Imaging in Older Adults. Journal of the American College of Cardiology, 2020, 76, 1577-1594.	2.8	21
222	Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. JAMA Network Open, 2021, 4, e2037438.	5.9	21
223	Prediction of severe coronary artery disease by combined rest and exercise radionuclide angiocardiography and tomographic perfusion imaging with technetium 99m-labeled sestamibi: A comparison with clinical and electrocardiographic data1. Journal of Nuclear Cardiology, 1997, 4, 189-194.	2.1	20
224	Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation. Journal of Cardiac Failure, 2014, 20, 23-30.	1.7	20
225	Rationale and design of a cluster-randomized multifaceted intervention trial to improve stroke care quality in China: The GOLDEN BRIDGE–Acute Ischemic Stroke. American Heart Journal, 2015, 169, 767-774.e2.	2.7	20
226	Depression Status Is Associated with Functional Decline Over 1-Year Following Acute Stroke. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1393-1399.	1.6	20
227	Socioeconomic, Psychosocial and Behavioral Characteristics of Patients Hospitalized With Cardiovascular Disease. American Journal of the Medical Sciences, 2017, 354, 565-572.	1.1	20
228	An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004675.	2.2	20
229	Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006322.	3.9	20
230	Thrombolysis in young adults with stroke. Neurology, 2019, 92, e2784-e2792.	1.1	20
231	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006548.	2.2	20
232	The Impact of High-Risk Cases on Hospitals' Risk-Adjusted Coronary Artery Bypass Grafting Mortality Rankings. Annals of Thoracic Surgery, 2015, 99, 856-862.	1.3	19
233	Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. JAMA Cardiology, 2016, 1, 655.	6.1	19
234	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	19

#	Article	IF	CITATIONS
235	Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 672-682.	2.9	19
236	Evaluating Health Technology Through Pragmatic Trials. JAMA - Journal of the American Medical Association, 2018, 320, 137.	7.4	19
237	The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19. PLoS ONE, 2021, 16, e0254809.	2.5	19
238	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	18
239	Cardioversion and subsequent quality of life and natural history of atrial fibrillation. American Heart Journal, 2017, 185, 59-66.	2.7	18
240	Racial Differences in Elevated Câ€Reactive Protein Among US Older Adults. Journal of the American Geriatrics Society, 2020, 68, 362-369.	2.6	18
241	Association of Evidence-Based Care Processes and Outcomes Among Patients With Acute Coronary Syndromes. Journal of Cardiovascular Nursing, 2008, 23, 50-55.	1.1	17
242	The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation inÂBleeding Rates Following PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 771-779.	2.9	17
243	Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. JAMA Cardiology, 2017, 2, 319.	6.1	17
244	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. Circulation, 2018, 137, 938-947.	1.6	17
245	International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Postâ€MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. Journal of the American Heart Association, 2018, 7, .	3.7	17
246	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2019, 214, 113-124.	2.7	17
247	Do patients treated at academic hospitals have better longitudinal outcomes after admission for non–ST-elevation myocardial infarction?. American Heart Journal, 2014, 167, 762-769.	2.7	16
248	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation: Cardiovascular Interventions, 2015, 8, e001712.	3.9	16
249	Safety and clinical effectiveness of drugâ€eluting stents for saphenous vein graft intervention in older individuals: Results from the medicareâ€inked National Cardiovascular Data Registry <sup>®</sup> Cath <scp>PCI</scp> Registry <sup>®</sup> (2005–2009). Catheterization and Cardiovascular Interventions. 2016. 87, 43-49.	1.7	16
250	Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG AD) Registry. Journal of the American Heart Association, 2016, 5, .	3.7	16
251	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation, 2017, 135, 38-47.	1.6	16

#	Article	IF	CITATIONS
253	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 263-272.	4.0	16
254	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart, 2020, 106, 358-364.	2.9	16
255	Sex disparities in patients with symptomatic severe aortic stenosis. American Heart Journal, 2021, 237, 116-126.	2.7	16
256	Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention. Stroke, 2022, 53, 1328-1338.	2.0	16
257	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. American Heart Journal, 2015, 169, 743-750.	2.7	15
258	Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S117-S124.	2.2	15
259	Ejection fraction, Bâ€ŧype natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. Clinical Cardiology, 2019, 42, 277-284.	1.8	15
260	Persistence of Evidence-Based Medication Use After Discharge from Academic Versus Nonacademic Hospitals Among Patients With Non–ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 114, 1479-1484.	1.6	14
261	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverterâ€Defibrillator for Primary Prevention. Journal of the American Heart Association, 2015, 4, e002061.	3.7	14
262	Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. American Heart Journal, 2015, 169, 266-273.	2.7	14
263	Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 145-151.	4.8	14
264	Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATEâ€ACS) Study. Journal of the American Heart Association, 2016, 5, .	3.7	14
265	Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. American Heart Journal, 2016, 179, 10-18.	2.7	14
266	Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 362-369.	3.6	14
267	Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2018, 200, 118-124.	2.7	14
268	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. Cardiovascular Diabetology, 2019, 18, 116.	6.8	14
269	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non–ST-segment elevation myocardial infarction. American Heart Journal, 2014, 167, 267-273.e1.	2.7	13
270	Identification of Hospital Outliers in Bleeding Complications After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 15-22.	2.2	13

#	Article	IF	CITATIONS
271	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. American Heart Journal, 2016, 177, 33-41.	2.7	13
272	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2016, 181, 145-152.	2.7	13
273	Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clinical Cardiology, 2017, 40, 746-751.	1.8	13
274	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2020, 226, 85-93.	2.7	13
275	Evaluating the Potential ???Economic Attractiveness??? of New Therapies in Patients with Non-ST Elevation Acute Coronary Syndrome. Pharmacoeconomics, 2000, 17, 263-272.	3.3	12
276	Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. Journal of the American Heart Association, 2015, 4, .	3.7	12
277	Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. Stroke, 2016, 47, 2066-2074.	2.0	12
278	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. Hypertension, 2017, 70, 907-914.	2.7	12
279	The burden of angina pectoris and its complications complications. Clinical Cardiology, 2007, 30, I10-I15.	1.8	11
280	Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes) Tj ETQq0 0	0 rgB <b>3.∤</b> Ovei	rlock110 Tf 50
281	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007124.	3.9	11
282	Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding. European Stroke Journal, 2020, 5, 47-55.	5.5	11
283	China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial. American Heart Journal, 2020, 227, 47-55.	2.7	11
284	Temporal Trends in Post Myocardial Infarction Heart Failure and Outcomes Among Older Adults. Journal of Cardiac Failure, 2022, 28, 531-539.	1.7	11
285	Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 1700-1702.	2.8	10
286	Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic Drugs. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 292-300.	2.2	10
287	Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	10
288	Site Principal Investigators in Multicenter Clinical Trials. Circulation, 2017, 135, 1185-1187.	1.6	10

#	Article	IF	CITATIONS
289	Glycemic control in patients undergoing coronary artery bypass graft surgery: Clinical features, predictors, and outcomes. Journal of Critical Care, 2017, 42, 328-333.	2.2	10
290	Challenges in Interpreting the Lipid-Lowering Trials. JAMA - Journal of the American Medical Association, 2018, 319, 1549.	7.4	10
291	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2018, 46, 346-350.	2.1	10
292	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	6.1	10
293	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 2019, 213, 81-90.	2.7	10
294	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the) Tj ETQq0 0 0	rgBT /Ove	rlock 10 Tf 50
295	An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial. American Heart Journal, 2019, 207, 49-57.	2.7	10
296	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 96, E102-E109.	1.7	10
297	Validation of the WATCHâ€DM and TRSâ€HF <sub>DM</sub> Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. Journal of the American Heart Association, 2022, 11, .	3.7	10
298	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace, 2014, 16, 1284-1290.	1.7	9
299	Comparison of Safety of Sotalol Versus Amiodarone inÂPatients With Atrial Fibrillation and Coronary Artery Disease. American Journal of Cardiology, 2014, 114, 716-722.	1.6	9
300	Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 567-575.	2.2	9
301	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATEâ€ACS) Study. Iournal of the American Heart Association. 2016. 5.	3.7	9
302	Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 109-116.	2.2	9
303	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. International Journal of Cardiology, 2017, 230, 301-303.	1.7	9
304	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Journal of Thrombosis and Thrombolysis, 2018, 46, 435-439.	2.1	9
305	Racial Differences in Long-Term Cardiovascular Outcomes. JACC: Cardiovascular Interventions, 2020, 13, 1596-1598.	2.9	9
306	Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease. American Heart Journal, 2021, 231, 36-44.	2.7	9

#	Article	IF	CITATIONS
307	The Contemporary Use of Angiography and Revascularization Among Patients With Non– <scp>ST</scp> â€Segment Elevation Myocardial Infarction in the United States Compared With South Korea. Clinical Cardiology, 2015, 38, 708-714.	1.8	8
308	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. Thrombosis and Haemostasis, 2016, 116, S33-S40.	3.4	8
309	New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation â^—. Journal of the American College of Cardiology, 2017, 69, 2485-2487.	2.8	8
310	When Less Is Not More â^—. Journal of the American College of Cardiology, 2017, 69, 2791-2793.	2.8	8
311	Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal, 2019, 210, 29-38.	2.7	8
312	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal, 2020, 219, 21-30.	2.7	8
313	Timeâ€Dependent Cardiovascular Treatment Benefit Model for Lipid‣owering Therapies. Journal of the American Heart Association, 2020, 9, e016506.	3.7	8
314	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	6.1	8
315	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. American Heart Journal, 2020, 225, 88-96.	2.7	8
316	Lipoprotein(a) Testing Patterns in a Large Health System. American Journal of Cardiology, 2021, 153, 43-50.	1.6	8
317	Association Between Patient Survival and Clinician Variability in Treatment Rates for Aortic Valve Stenosis. Journal of the American Heart Association, 2021, 10, e020490.	3.7	8
318	Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non–ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). American Journal of Cardiology, 2015, 115, 1655-1660.	1.6	7
319	Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome. Annals of Thoracic Surgery, 2017, 104, 98-105.	1.3	7
320	Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease. American Heart Journal, 2018, 206, 51-60.	2.7	7
321	Opportunities for improving use of evidenceâ€based therapy in patients with type 2 diabetes and cardiovascular disease. Clinical Cardiology, 2019, 42, 1063-1070.	1.8	7
322	Adolescent and Young Adult Recreational, Occupational, and Transportation Activity: Activity Recommendation and Weight Status Relationships. Journal of Adolescent Health, 2019, 65, 147-154.	2.5	7
323	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. American Heart Journal, 2019, 218, 100-109.	2.7	7
324	Time to benefit and harm of intensive blood pressure treatment: insights from SPRINT. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, e1-e2.	4.0	7

#	Article	IF	CITATIONS
325	Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006019.	2.2	7
326	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). American Journal of Cardiology, 2020, 125, 1655-1660.	1.6	7
327	Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e009963.	3.9	7
328	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation, 2016, 134, 1122-1124.	1.6	6
329	Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBITâ€AF Registry. Clinical Cardiology, 2016, 39, 119-125.	1.8	6
330	Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure. Lancet Diabetes and Endocrinology,the, 2017, 5, 325-326.	11.4	6
331	Outcomes of a multiâ€community hypertension implementation study: the American Heart Association's Check. Change. <i>Control</i> . program. Journal of Clinical Hypertension, 2017, 19, 479-487.	2.0	6
332	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men—Reply. JAMA Cardiology, 2017, 2, 108.	6.1	6
333	Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBITâ€AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. Journal of the American Heart Association, 2018, 7, .	3.7	6
334	The association of pre- and posthospital medication adherence in myocardial infarction patients. American Heart Journal, 2019, 208, 74-80.	2.7	6
335	Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications. JAMA Cardiology, 2020, 5, 38.	6.1	6
336	Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time—Insights from the SPRINT Trial. American Journal of Medicine, 2020, 133, e369-e370.	1.5	6
337	Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. American Journal of Cardiology, 2021, 138, 26-32.	1.6	6
338	Generating evidence for therapeutic effects: the need for well-conducted randomized trials. Journal of Clinical Investigation, 2021, 131, .	8.2	6
339	Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke. JAMA Internal Medicine, 2022, 182, 559.	5.1	6
340	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. American Heart Journal, 2015, 170, 706-714.	2.7	5
341	Genetic Studies Help Clarify the Complexities of Lipid Biology and Treatment. JAMA - Journal of the American Medical Association, 2017, 318, 915.	7.4	5
342	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1732-1739.	4.4	5

#	Article	IF	CITATIONS
343	Finding Means to Fulfill the Societal and Academic Imperative for Open Data Access and Sharing. JAMA Cardiology, 2018, 3, 793.	6.1	5
344	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006182.	2.2	5
345	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal of Cardiovascular Drugs, 2021, 21, 553-561.	2.2	5
346	Prospective evaluation of lipid management following acute coronary syndrome in <scp>nonâ€Western</scp> countries. Clinical Cardiology, 2021, 44, 955-962.	1.8	5
347	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Network Open, 2021, 4, e2117963.	5.9	5
348	Identifying Nonclinical Factors Associated With 30-Day Readmission in Patients with Cardiovascular Disease: Protocol for an Observational Study. JMIR Research Protocols, 2017, 6, e118.	1.0	5
349	Risk-Adjusted, 30-Day Home Time After Transcatheter Aortic Valve Replacement as a Hospital-Level Performance Metric. Journal of the American College of Cardiology, 2022, 79, 132-144.	2.8	5
350	Health Economics of Acute Coronary Syndromes. Journal of Thrombosis and Thrombolysis, 1998, 5, S161-S168.	2.1	4
351	The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice. American Heart Journal, 2014, 167, 466-471.	2.7	4
352	Use of Implantable Cardioverter-Defibrillators Among Medicare Patients—Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1874.	7.4	4
353	How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?. American Heart Journal, 2018, 196, 163-169.	2.7	4
354	Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. American Heart Journal, 2019, 218, 92-99.	2.7	4
355	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. American Heart Journal, 2019, 218, 57-65.	2.7	4
356	Prevalence and Management of Adult Obesity in a Large U.S. Academic Health System. American Journal of Preventive Medicine, 2020, 58, 817-824.	3.0	4
357	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Non–ST-Segment–Elevation Myocardial Infarction for Intensive Care Unit Admission. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007602.	2.2	4
358	Vision and Creation of the American Heart Association Pharmaceutical Roundtable Outcomes Research Centers. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 663-670.	2.2	3
359	The Association of Transfer Rate From Hospitals Without Revascularization Capabilities and Mortality Risk for Older Non– <scp>ST</scp> ‣egment Elevation Myocardial Infarction Patients. Clinical Cardiology, 2015, 38, 733-739.	1.8	3
360	Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IVâ€: Circulation, 2015, 132, e29.	1.6	3

#	Article	IF	CITATIONS
361	"Sticky―Issues for Adherence in Secondary Prevention. Journal of the American College of Cardiology, 2017, 70, 1555-1557.	2.8	3
362	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	2.7	3
363	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. American Heart Journal, 2020, 220, 82-88.	2.7	3
364	Deprescribing Antihypertensive Medications for Patients Aged 80 Years or Older. JAMA - Journal of the American Medical Association, 2020, 323, 2024.	7.4	3
365	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 128-135.	1.7	3
366	Sequential Evolution of Quality Assessment for Aortic Valvular Heart Interventions. Circulation, 2021, 144, 195-198.	1.6	3
367	Perceived Versus Actual Risks of 30-Day Readmission in Patients With Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006586.	2.2	3
368	Progress Against Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1979.	7.4	2
369	Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease― Circulation, 2015, 132, e203.	1.6	2
370	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program― Circulation, 2017, 135, e22-e23.	1.6	2
371	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATEâ€ACS (Treatment With ADP Receptor) Tj ET	Qq1 <u>1</u> 0.78	4314 rgBT /O
372	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. International Journal of Cardiology, 2019, 289, 58-62.	1.7	2
373	Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Treatment Among Morbidly Obese Patients with Venous Thromboembolism. Blood, 2018, 132, 2537-2537.	1.4	2
374	Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke, 2021, 52, e777-e781.	2.0	2
375	Strategies to Overcome Medication Nonadherence—Reply. JAMA - Journal of the American Medical Association, 2014, 311, 1693.	7.4	1
376	Open Access Platforms for Sharing Clinical Trial Data—Reply. JAMA - Journal of the American Medical Association, 2016, 316, 666.	7.4	1
377	A New Personalized, Patient-Centric, and Cost-Conscious Guideline for Contemporary Cholesterol Management. JAMA - Journal of the American Medical Association, 2019, 321, 749.	7.4	1
378	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. Circulation: Cardiovascular Interventions, 2019, 12, e008160.	3.9	1

#	Article	IF	CITATIONS
379	Translating the Secondary Prevention Therapeutic Boom Into Action. JAMA Cardiology, 2020, 5, 215.	6.1	1
380	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation: Cardiovascular Interventions, 2020, 13, e008274.	3.9	1
381	The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease. Atherosclerosis, 2021, 321, 1-7.	0.8	1
382	Prognostic/Clinical Prediction Models: Using Observational Data to Estimate Prognosis: An Example Using a Coronary Artery Disease Registry. , 2005, , 287-314.		0
383	Insurance Coverage and Care of Patients with Non–ST-Segment Elevation Acute Coronary Syndromes. Annals of Internal Medicine, 2007, 147, 212.	3.9	Ο
384	Revascularization in Stable Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2014, 312, 2028.	7.4	0
385	Examination of the Treatment Selection Process in a Multicenter Observational Study. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 764-769.	2.2	0
386	Smoke Signals. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	0
387	<i>JAMA</i> Cardiovascular Disease Theme Issue. JAMA - Journal of the American Medical Association, 2015, 313, 1718.	7.4	0
388	The Lasker Awards—Recognizing and Valuing Investments in Cardiovascular Research. JAMA - Journal of the American Medical Association, 2015, 314, 1121.	7.4	0
389	Selecting the Duration of AntiplateletÂTherapy Following Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 68, 1865-1867.	2.8	0
390	Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs. American Heart Journal, 2018, 196, 170-177.	2.7	0
391	Association between intensive care unit utilization for patients with non–ST-segment elevation myocardial infarction and patient experience. American Heart Journal, 2021, 231, 32-35.	2.7	0
392	Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?. American Journal of Cardiology, 2021, 142, 83-90.	1.6	0
393	Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry. Circulation, 2014, 130,	1.6	0
394	Abstract 12266: Treatment and Outcomes of Dual Medicare/Medicaid Eligible Older Adults With Myocardial Infarction. Circulation, 2015, 132, .	1.6	0
395	Telehealth and 30-Day Readmissions Among Heart Failure Patients During the COVID-19 Pandemic. Innovation in Aging, 2021, 5, 465-466.	0.1	0
396	Abstract 21161: Use of an Open Access Multi-Sponsor Data Sharing Platform in Cardiology. Circulation, 2017, 136, .	1.6	0

#	Article	IF	CITATIONS
397	The HEART Pathway: Just A Heart Score Permutation or the Future of Clinical Decision Rules?. Academic Emergency Medicine, 0, , .	1.8	Ο